ImmunityBio is on a Mission

To continuously pursue new therapies that kill disease, not the immune system

A Culture Where Patients Come First

The people of ImmunityBio work tirelessly to transform our living biological technologies into innovative treatments that will improve the lives of people around the world. Our goal is to leverage and harmonize with the body’s immune system to clear disease while ensuring our therapies also protect the immune system from damage. ImmunityBio’s major focus is the development of novel treatments for advanced cancers and infectious diseases. We believe our science has the potential to change the current paradigm of care for these diseases.

We do so with a combination of highly experienced and talented people, deep scientific knowledge, and advanced research and manufacturing facilities. Together, they enable us to invent, test, and market innovative, effective, and safe therapies that address some of the greatest needs in medicine. We measure our success by the quality of life we can offer to patients.

Our History

Over the last two decades, our Executive Chairman and Global Chief Scientific and Medical Officer, Dr. Patrick Soon-Shiong, M.D., has investigated mechanisms to activate the immune system to attack tumors that can otherwise evade and escape the body’s defense mechanisms. After inventing the world’s first protein nanoparticle drug, Abraxane®, Dr. Soon-Shiong turned his focus to the next-generation of immunotherapies. ImmunityBio was founded in 2014 to create innovative immunotherapies that address serious unmet needs in oncology and infectious disease.

Since then we have progressed into a clinical-stage biotechnology company with 27 clinical trials—18 of which are in Phase 2 or 3 development—across 13 indications in liquid and solid tumors. Our proprietary natural killer cell platform can be easily expanded, genetically modified, and cryopreserved and offers multiple modes of cytotoxicity. Our lead antibody cytokine fusion protein, Anktiva (N-803), has received FDA Breakthrough Therapy designation for BCG-unresponsive non-muscle invasive bladder cancer. Our work is led by a senior team with highly complementary and broad expertise across novel scientific areas including genomics and proteomics, monoclonal antibodies, fusion proteins, vaccines and autologous and allogeneic cell therapies, based on experiences at companies ranging from biotech startups to large commercial pharmaceutical enterprises.


Rich Adcock
President & Chief Executive Officer, ImmunityBio
At ImmunityBio, we never lose sight of who we serve: people with serious diseases who may be helped by the innovative therapies we conceive, design, and develop. It’s those people who inspire our team of scientists, doctors, and staff every day.
Dr. Patrick Soon-Shiong
Executive Chairman and Global Chief Scientific and Medical Officer, ImmunityBio
By 1990, we recognized that the key immune cell type involved in organ rejection following transplantation and in killing cancer cells was the natural killer (NK) cell – ‘nature’s first responder’. The isolation of the NK cells by Dr. Hans Klingemann in 1992 that became the NK-92 cell line, set us on our current course of developing NK cell-based therapies for the treatment of cancer and infectious disease.

How Can ImmunityBio Help You?

Solutions for Patients

Many cancer therapies, including radiation therapy, chemotherapy, CAR-T therapy, and B-cell immunotherapy, severely weaken the immune system—the human body’s most important natural disease-fighting weapon. But ImmunityBio creates targeted, personalized immunotherapies that are designed to strengthen the immune system and enable it to outsmart your disease.

Opportunities for Trial Investigators

The broad therapeutic potential and demonstrated safety of ImmunityBio’s immune-enhancing IL-15 superagonist Anktiva (N-803), engineered NK-92® cell-based therapies, and our next-generation adenovirus-vectored anti-cancer vaccines make them appealing therapeutics for testing by trial investigators who want to make a contribution to clinical cancer research. Interested clinicians and other are encouraged to contact ImmunityBio to find out how they may support discovery of future cancer treatments.

Tools for Research Scientists

Our NK-92® easy-to-maintain and highly cytotoxic natural killer cell line provides a versatile bioanalytical testing tool that can help researchers develop functional killing assays that are more consistent and reliable than donor blood and reporter gene assays.

A Robust Clinical Pipeline

ImmunityBio’s immunotherapies for treating cancer and infectious diseases are currently being studied in a range of clinical trials at various stages.

Meet the Team

Patrick Soon-Shiong, M.D.Executive Chairman of the Board Bio
Rich AdcockPresident & Chief Executive Officer Bio
David SachsChief Financial Officer Bio
Leonard S. Sender, M.D.Chief Operating Officer Bio
Sandeep “Bobby” Reddy, M.D.Chief Medical Officer Bio
Sarah Singleton Chief Communications Officer & Head of Patient Advocacy Bio
Jason Liljestrom, Esq. General Counsel Bio
Regan Lauer
Regan LauerChief Accounting Officer Bio
Barry Simon, M.D.Chief Corporate Affairs Officer Bio
Hans Klingemann, M.D., Ph.D.Chief Science Officer – Cellular Bio
Manju Saxena, Ph.D.Senior Vice President of Product Development, Cell Therapy Program Bio
Elizabeth GabitzschSenior Vice President, Product Development & Vaccine Programs Bio
Enrique Diloné
Enrique Diloné, Ph.D.Chief Technology Officer Bio

Board of Directors

Patrick Soon-Shiong, M.D.Executive Chairman of the Board Bio
Rich AdcockPresident & Chief Executive Officer Bio
Cheryl Cohen Bio
Michael Blaszyk
Michael Blaszyk Bio
John Brennan Bio
Linda Maxwell
Linda Maxwell, M.D. Bio
Wesley Clark Bio
Christobel Selecky Bio
Barry Simon, M.D.Chief Corporate Affairs Officer Bio

Developing innovative, disease-altering therapies for those who need them the most